SCHEDULE 13D/A: General Atlantic Amends Stake in Third Harmonic Bio, Reaffirming 8.0% Beneficial Ownership
Schedule 13D/A Amendment
General Atlantic and its affiliated entities have filed an Amendment No. 1 to their Schedule 13D, reaffirming their beneficial ownership of 8.0% of Third Harmonic Bio, Inc.'s common stock and outlining their investment intentions.
Summary
- General Atlantic and its affiliated entities (the "Reporting Persons") filed an Amendment No. 1 to their Schedule 13D regarding Third Harmonic Bio, Inc. (the "Company").
- The Reporting Persons collectively beneficially own 3,623,910 shares of Third Harmonic Bio, Inc. common stock.
- This ownership represents approximately 8.0% of the 45,058,413 shares of common stock reported by the Company as outstanding as of November 1, 2024, in its Quarterly Report on Form 10-Q.
- The shares were acquired for investment purposes, with funds obtained from contributions from the GA Funds and Sponsor Coinvestment Funds.
- The Reporting Persons may engage in communications with the Company's management, board, and other stockholders, and may make suggestions regarding operations, strategy, and board composition.
- They retain flexibility to increase or decrease their investment position, make additional purchases in the open market or private transactions, or dispose of shares, based on market conditions and the Company's performance.
- Recent purchases of common stock were effected through open market transactions on the Nasdaq Stock Market LLC, with specific trades occurring between December 12, 2024, and January 22, 2025, at prices ranging from $5.72 to $11.44 per share.
- The filing updates the original Schedule 13D filed on September 28, 2022.
Sentiment
Score: 6
Explanation: The filing is a routine amendment to a Schedule 13D, indicating General Atlantic's continued significant beneficial ownership in Third Harmonic Bio, Inc. and outlining their investment intentions. While it doesn't contain new positive or negative operational news from the company, the continued substantial stake by a prominent investment firm can be viewed as a neutral to slightly positive signal of ongoing investor interest.
Positives
- General Atlantic, a prominent investment firm, maintains a substantial 8.0% stake in Third Harmonic Bio, Inc., indicating continued investment interest.
- The Reporting Persons' stated intent to engage with the Company's management and board suggests potential for active shareholder involvement aimed at enhancing company value.
- The flexibility to increase their investment position signals potential for further capital commitment if market conditions and company performance are favorable.
Risks
- The Reporting Persons' investment position may be increased or decreased depending on the Company's performance and other market conditions, indicating market risk for their investment.
- Future actions, including additional purchases or dispositions, are subject to various factors such as the Company's business, prospects, financial condition, the market for common stock, general economic conditions, and stock market conditions.
Future Outlook
The Reporting Persons may increase or decrease their investment position in Third Harmonic Bio, Inc. common stock, make additional purchases in the open market or privately, or dispose of all or part of their investments, and/or enter into derivative transactions. These actions will depend on the Company's performance, market conditions, available opportunities, general economic conditions, and other factors. They also expect to review their investment position from time to time.
Industry Context
This filing is a standard disclosure of a significant investor's stake and intentions in a publicly traded biotechnology company. It does not provide specific industry trends or competitive analysis. General Atlantic is a global growth equity firm, and their investment in Third Harmonic Bio, Inc. aligns with their strategy of investing in various companies for investment purposes.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Shareholder Rights Agreement | An Amended and Restated Investors' Rights Agreement, dated December 17, 2021, grants General Atlantic (through GA TH) and other shareholders customary demand registration and piggyback registration rights. | 2021-12-17 | Provides significant shareholders with rights to register and sell their shares, potentially impacting liquidity and future share offerings. |
Related Party Transactions
- The GA Funds and the Sponsor Coinvestment Funds, which are part of the General Atlantic group, contributed the capital to fund the IPO and share beneficial ownership of the common stock held of record by GA TH.
- The Amended and Restated Investors' Rights Agreement, dated December 17, 2021, is by and among the Company, GA TH (an entity within the General Atlantic group), and other shareholders, granting certain registration rights.
Stakeholder Impact
- Shareholders: The filing indicates a significant institutional investor (General Atlantic) maintains a substantial stake, which could be viewed positively. Their stated intent to engage with management and potentially influence strategic decisions could impact shareholder value. The possibility of future share purchases or dispositions by General Atlantic could affect market liquidity and share price.
- Management/Board: General Atlantic's stated intention to communicate with and make suggestions to management and the board implies potential for active shareholder engagement and influence on corporate strategy and governance.
Next Steps
- Reporting Persons may engage in communications with Third Harmonic Bio, Inc. stockholders, management, and board of directors.
- Reporting Persons may make suggestions concerning the Company's operations, prospects, business and financial strategies, strategic transactions, assets and liabilities, business and financing alternatives, and the composition of the board of directors.
- Reporting Persons expect to review their investment position in the common stock or the Company from time to time.
- Reporting Persons may increase or decrease their investment position in the common stock.
- Reporting Persons may make additional purchases of common stock either in the open market or in privately-negotiated transactions.
- Reporting Persons may decide to hold or dispose of all or part of their investments in the common stock.
- Reporting Persons may enter into derivative transactions with institutional counterparties with respect to the Company's securities.
Key Dates
| Date | Description |
|---|---|
| 2021-12-17 | Date of the Amended and Restated Investors' Rights Agreement. |
| 2022-07-21 | Date of the Joint Filing Agreement among the Reporting Persons. |
| 2022-08-23 | Date the Investors' Rights Agreement was filed as Exhibit 4.2 to the Issuer's Registration Statement on Form S-1. |
| 2022-09-28 | Date the original Schedule 13D was filed with the U.S. Securities and Exchange Commission. |
| 2024-11-01 | Date as of which 45,058,413 shares of common stock were reported outstanding by the Company in its Form 10-Q. |
| 2024-11-07 | Date the Company's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2024-12-12 | Trade date for 138,614 shares of common stock at $11.44 per share. |
| 2024-12-13 | Trade date for 27,130 shares of common stock at $11.14 per share. |
| 2024-12-17 | Trade date for 5,000 shares of common stock at $11.27 per share. |
| 2024-12-18 | Trade date for 125,000 shares of common stock at $11.25 per share. |
| 2024-12-19 | Trade date for 25,000 shares of common stock at $10.97 per share. |
| 2024-12-20 | Trade date for 75,000 shares of common stock at $10.69 per share. |
| 2024-12-30 | Trade date for 17,817 shares of common stock at $10.36 per share. |
| 2025-01-17 | Date of event which required the filing of this statement; also trade date for 41,384 shares of common stock at $5.72 per share. |
| 2025-01-21 | Trade date for 85,203 shares of common stock at $6.18 per share. |
| 2025-01-22 | Trade date for 125,000 shares of common stock at $6.00 per share; also the signature date of the filing. |
Keywords
Third Harmonic Bio, General Atlantic, SEC filing, Schedule 13D/A, beneficial ownership, common stock, investment, shareholder, biotechnology, THRD
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.